Atricure, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

19 Feb 2026

ATRC

10-K: AtriCure Reports Strong 2025 Revenue Growth, Net Loss Narrows

AtriCure, Inc. announced its 2025 annual results, reporting a 14.9% increase in worldwide revenue to $534.5 million, driven by strong adoption of pain management, open ablation, and appendage management products, while net loss significantly narrowed to $11.4 million.

NASDAQ

14 Feb 2025

ATRC

Atricure, INC

10-K: AtriCure Reports 16.5% Revenue Growth in 2024, Driven by Product Innovation and Strategic Initiatives

AtriCure's 2024 10-K filing reveals a 16.5% increase in revenue, fueled by product innovation, clinical science investments, and physician education.

NASDAQ

16 Feb 2024

ATRC

Atricure, INC

10-K: AtriCure Grants Stock Incentives and Outlines Employee Agreements

AtriCure, Inc. has issued stock incentive plans and restricted stock awards to employees, detailing vesting schedules, forfeiture conditions, and compliance requirements.